Overview
Trenchant Biosystems develops the AutoCell platform for automating patient-specific cell and gene therapy (CGT) manufacturing, enabling scalable production in ISO class 7 environments at the place of care. The technology uses microbubble separation to achieve 7-fold higher gene-modified cell yields, reduce costs by up to 80%, and shorten vein-to-vein timelines from six weeks to 2.5 days. Partnerships with Invetech, UMass Chan Medical School, and Caring Cross advance the platform toward fully automated commercial products for applications like sickle cell disease therapies.
Frequently asked questions
- What is the AutoCell platform's key technology?
- AutoCell automates CGT manufacturing with microbubble separation instead of immunomagnetic beads, supporting washing, selection, and transduction for higher yields and lower costs.
- What manufacturing time and cost reductions does AutoCell offer?
- It reduces vein-to-vein timelines to 2.5 days from six weeks and costs by up to 80%, using 25% of a fresh apheresis collection for clinical doses.
- What are Trenchant Biosystems' key partnerships and development stage?
- Strategic alliance with Invetech for full automation from prototype; collaborations with UMass Chan and Caring Cross for HSC therapies targeting SCD, planning FDA INTERACT in 2027.